Aclaris Therapeutics, Inc.ACRSNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank50
3Y CAGR-8.6%
5Y CAGR+9.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-8.6%/yr
vs -6.1%/yr prior
5Y CAGR
+9.5%/yr
Recent deceleration
Acceleration
-2.5pp
Decelerating
Percentile
P50
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $82.11M | -48.0% |
| 2024 | $157.86M | +42.8% |
| 2023 | $110.53M | +2.7% |
| 2022 | $107.65M | +17.3% |
| 2021 | $91.77M | +75.6% |
| 2020 | $52.26M | -43.6% |
| 2019 | $92.73M | -33.1% |
| 2018 | $138.66M | +90.2% |
| 2017 | $72.90M | +50.1% |
| 2016 | $48.57M | - |